Comparison of JAK/STAT inhibitor safety profiles: incidence per 100 patient years (PYs) exposure in RA
| Tofacitinib58 JAK 3/1/2, phases II and III 5 mg and 10 mg, n=7061 | Baricitinib59 JAK 1/2, phase III 2 mg and 4 mg, n=3770 | Upadacitinib60 61 JAK 1/2, phase III 15 mg, n=2629 | Filgotinib62 63 JAK 1, phases I–III 100 mg and 200 mg, n=3691 | |
| PYs/median follow-up | 22 874/3.1 years | 13 148/4.2 years | 4566/1.7 years | 6081/1.6 years |
| SIEs | 2.5 | 2.7 | 3.2 | 1.8 |
| OIs | 0.4 | 0.5 | 0.7 | 0.1 |
| Tb | 0.2 | 0.2 | 2.3 | <0.1 |
| Herpes zoster: non-serious and serious | 3.6 | 3.0 | 3.4 | 1.6 |
| Malignancy (excluding NMSC) | 0.8 | 0.9 | 0.9 | 0.5 |
| Lymphoma | 0.05 | 0.06 | NR | NR |
| NMSC | 0.6 | 0.3 | 0.3 | 0.2 |
| MACE | 0.4 | 0.5 | 0.5 | 0.6 |
| DVT/PE | 0.3 | 0.5 | 0.5 | 0.15 |
| GI perforations | 0.1 | 0.04 | 0.05 | <0.1 |
DVT/PE, deep vein thrombosis/pulmonary embolism; MACE, major cardiovascular event; NMSC, non-melanoma skin cancers; NR, not reported; OIs, opportunistic infections; RA, rheumatoid arthritis; SIEs, serious infections; Tb, Tuberculosis.